Compare FNWB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | GNLX |
|---|---|---|
| Founded | 1923 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.1M | 202.4M |
| IPO Year | 2015 | 2023 |
| Metric | FNWB | GNLX |
|---|---|---|
| Price | $9.40 | $3.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $13.50 | ★ $19.75 |
| AVG Volume (30 Days) | 40.8K | ★ 135.3K |
| Earning Date | 01-28-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,052,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $1.99 |
| 52 Week High | $12.10 | $8.54 |
| Indicator | FNWB | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.19 | 28.76 |
| Support Level | $9.26 | $3.32 |
| Resistance Level | $9.48 | $4.99 |
| Average True Range (ATR) | 0.15 | 0.34 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 23.65 | 6.59 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.